Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephapirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 4/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.84 |
| ▸ | BLM | P54132 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephapirin SCHEMBL9437558 | 1.00 | TDP1 (1.00) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL23630215 | 0.99 | TDP1 (0.98) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL28121684 | 0.93 | TDP1 (0.86) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL3205 | 0.92 | NR1I2 (1.00) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL11844793 | 0.92 | NR1I2 (1.00) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL8194062 | 0.92 | NR1I2 (1.00) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL16072823 | 0.92 | NR1I2 (1.00) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL11844804 | 0.92 | NR1I2 (1.00) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL151779 | 0.91 | NR1I2 (0.98) | TDP1MAPTHSD17B10CYP3A4KDM4E | |
| Cephapirin SCHEMBL28932665 | 0.91 | NR1I2 (0.98) | TDP1MAPTHSD17B10CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3448 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| CN-112912386-A | Cell penetrating peptide based on influenza virus M2 protein | 中国医学科学院基础医学研究所 | 2021-06-04 | — | — | CN | claimed |
| US-20200246573-A1 | NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS | STREETERVILLE CAPITAL, LLC | 2020-08-06 | — | — | US | claimed |
| CN-107417704-B | Method for refining cefapirin sodium | 齐鲁晟华制药有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | claimed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0536360-A4 | TOPICAL TREATMENT OF ACNE | — | 1993-08-04 | — | — | EP | claimed |
| EP-0536360-A1 | TOPICAL TREATMENT OF ACNE | BLOOM, Leonard (US) | 1993-04-14 | — | — | EP | claimed |
| WO-1992015299-A1 | TOPICAL TREATMENT OF ACNE | BLOOM, LEONARD (US) | 1992-09-17 | — | — | WO | claimed |